572 related articles for article (PubMed ID: 33684837)
1. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
Mollaei M; Hassan ZM; Khorshidi F; Langroudi L
Transl Oncol; 2021 May; 14(5):101056. PubMed ID: 33684837
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs.
Friedman JR; Richbart SD; Merritt JC; Perry HE; Brown KC; Akers AT; Nolan NA; Stevenson CD; Hurley JD; Miles SL; Tirona MT; Valentovic MA; Dasgupta P
Adv Cancer Res; 2019; 144():263-298. PubMed ID: 31349900
[TBL] [Abstract][Full Text] [Related]
4. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
Alimbetov D; Askarova S; Umbayev B; Davis T; Kipling D
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882812
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone-chemotherapeutic combinations: new regimen to combat cancer and cancer stem cells.
El-Far AH; Tantawy MA; Al Jaouni SK; Mousa SA
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1581-1598. PubMed ID: 32458010
[TBL] [Abstract][Full Text] [Related]
9. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
10. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells.
Yuksel A; Bildik G; Senbabaoglu F; Akin N; Arvas M; Unal F; Kilic Y; Karanfil I; Eryılmaz B; Yilmaz P; Ozkanbaş C; Taskiran C; Aksoy S; Guzel Y; Balaban B; Ince U; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2926-35. PubMed ID: 26466914
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
12. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents.
Kikuchi H; Yuan B; Hu X; Okazaki M
Am J Cancer Res; 2019; 9(8):1517-1535. PubMed ID: 31497340
[TBL] [Abstract][Full Text] [Related]
13. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
14. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.
Di Desidero T; Orlandi P; Fioravanti A; Alì G; Cremolini C; Loupakis F; Gentile D; Banchi M; Cucchiara F; Antoniotti C; Masi G; Fontanini G; Falcone A; Bocci G
Biochem Pharmacol; 2019 Jun; 164():94-105. PubMed ID: 30953637
[TBL] [Abstract][Full Text] [Related]
16. Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents.
Ralph SJ; Low P; Dong L; Lawen A; Neuzil J
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):327-46. PubMed ID: 18221044
[TBL] [Abstract][Full Text] [Related]
17. Modulating MGMT expression through interfering with cell signaling pathways.
Bai P; Fan T; Wang X; Zhao L; Zhong R; Sun G
Biochem Pharmacol; 2023 Sep; 215():115726. PubMed ID: 37524206
[TBL] [Abstract][Full Text] [Related]
18. Treatment duration with immune-based therapies in Cancer: an enigma.
Bantia S; Choradia N
J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies.
Su JX; Li SJ; Zhou XF; Zhang ZJ; Yan Y; Liu SL; Qi Q
Acta Pharmacol Sin; 2023 Sep; 44(9):1725-1736. PubMed ID: 37169853
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
